X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
DISC-1459 (bitopertin) is an investigational, clinical-stage, orally-administered inhibitor of glycine transporter 1 (GlyT1) that is designed to modulate heme biosynthesis. It is being evaluated for the treatment of erythropoietic protoporphyria.
Lead Product(s): Bitopertin
Therapeutic Area: Genetic Disease Product Name: DISC-1459
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2024
Details:
DISC-0974 is an investigational monoclonal antibody targeting a BMP-signaling co-receptor called hemojuvelin (HJV). It is being developed for the treatment of anemia in non-dialysis dependent chronic kidney disease.
Lead Product(s): DISC-0974
Therapeutic Area: Nephrology Product Name: DISC-0974
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
9MW3011 is an anti-TMPRSS6 antibody which can upregulate the level of hepcidin expressed by hepatocytes through specific binding. It is being evaluated for the treatment of β-thalassemia and polycythemia vera.
Lead Product(s): 9MW3011
Therapeutic Area: Genetic Disease Product Name: DISC-3405
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Mabwell
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
DISC-3405 is an investigational, anti-TMPRSS6 (Matriptase-2) monoclonal antibody designed to increase hepcidin production and suppress serum iron. It is under development for the treatment of polycythemia vera.
Lead Product(s): DISC-3405
Therapeutic Area: Oncology Product Name: DISC-3405
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2024
Details:
MWTX-003, also known as DISC-3405, is an investigational, anti-TMPRSS6 monoclonal antibody, which is investigated for the treatment of patients with polycythemia vera.
Lead Product(s): DISC-3405
Therapeutic Area: Oncology Product Name: MWTX-003
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2023
Details:
MWTX-003, also known as DISC-3405, is an investigational, anti-TMPRSS6 monoclonal antibody, which is investigated for the treatment of patients with polycythemia vera.
Lead Product(s): DISC-3405
Therapeutic Area: Oncology Product Name: MWTX-003
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Mabwell
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2023
Details:
DISC-1459 (bitopertin) is an investigational, clinical-stage, orally-administered inhibitor of glycine transporter 1 (GlyT1) that is designed to modulate heme biosynthesis, which is investigated for the treatment of diamond-blackfan anemia.
Lead Product(s): Bitopertin
Therapeutic Area: Genetic Disease Product Name: DISC-1459
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2023
Details:
The proceeds will fund research and clinical development of Disc's candidates including, DISC-1459 (bitopertin), a first-in-class, oral small molecule inhibitor of glycine transporter 1, to treat erythropoietic porphyrias, a rare, genetically-driven hematologic diseases.
Lead Product(s): Bitopertin
Therapeutic Area: Rare Diseases and Disorders Product Name: DISC-1459
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $157.8 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 22, 2023
Details:
The proceeds will fund research and clinical development of Disc's candidates including, DISC-1459 (bitopertin), a first-in-class, oral small molecule inhibitor of glycine transporter 1, to treat erythropoietic porphyrias, a rare, genetically-driven hematologic diseases.
Lead Product(s): Bitopertin
Therapeutic Area: Rare Diseases and Disorders Product Name: DISC-1459
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $137.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 13, 2023
Details:
The proceeds will fund research and clinical development of Disc's candidates including, DISC-1459 (bitopertin), a first-in-class, oral small molecule inhibitor of glycine transporter 1, to treat erythropoietic porphyrias, a rare, genetically-driven hematologic diseases.
Lead Product(s): Bitopertin
Therapeutic Area: Rare Diseases and Disorders Product Name: DISC-1459
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 12, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
